<code id='7B544E9B37'></code><style id='7B544E9B37'></style>
    • <acronym id='7B544E9B37'></acronym>
      <center id='7B544E9B37'><center id='7B544E9B37'><tfoot id='7B544E9B37'></tfoot></center><abbr id='7B544E9B37'><dir id='7B544E9B37'><tfoot id='7B544E9B37'></tfoot><noframes id='7B544E9B37'>

    • <optgroup id='7B544E9B37'><strike id='7B544E9B37'><sup id='7B544E9B37'></sup></strike><code id='7B544E9B37'></code></optgroup>
        1. <b id='7B544E9B37'><label id='7B544E9B37'><select id='7B544E9B37'><dt id='7B544E9B37'><span id='7B544E9B37'></span></dt></select></label></b><u id='7B544E9B37'></u>
          <i id='7B544E9B37'><strike id='7B544E9B37'><tt id='7B544E9B37'><pre id='7B544E9B37'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:entertainment    Page View:39
          Two Vertex buidings in the Seaport District
          David L Ryan/Globe Staff

          When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of new development.

          Now, Vertex may be on the move again.

          advertisement

          With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more
          30 years of 'Listening to Prozac'
          30 years of 'Listening to Prozac'

          WhenProzacfirstenteredthepsychiatrysceneininthelate’80s,theprofessionwasstillFreud’sterritory.Manyco

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          FDA investigates CAR

          TheFDAislookingintoadverseeventsinvolvinganumberofCAR-Ttherapies,includingBreyanzi.Illustration:STAT